Dr. Menashe Levy
CTO and Cofounder at Clexio Biosciences Ltd.

Menashe is an entrepreneur, with over 25 years of product development experience and successful track record in progressing new technologies from an idea to advanced clinical development and global commercial stages.

Prior to co-founding Clexio, Menashe served in a variety of executive roles and as cofounder in innovation-driven, successful drug-discovery, bio-pharmaceutical, device and combo device-drug companies.

Prior to joining Clexio, Menashe was the CTO of Teva Pharmaceutical Global R&D. Before that, he served as VP for R&D at Aposense (TASE:APOS), a drug discovery company developing rationally - designed small molecules for treatment of multiple disease categories. Previously, he held the position of VP for R&D at Regentis Biomaterials, focused on the development of hydrogel implantable scaffold for cartilage regeneration. Formerly, he held the position of VP R&D at ColBar Lifesience that developed and globally commercialized biomaterial products for aesthetic and dental markets. Following the acquisition of Colbar by J&J, he served as VP for medical relationships and life cycle management at J&J consumer division. Earlier, he served as CTO of Rostam Ltd. and as a cofounder and CEO of its daughter company, HiGienic Intravaginal Technologies Ltd, which developed and commercialized the first, FDA approved, tampon drug delivery product. Menashe was also co-founder and VP of R&D and Operations of Gamida-Cell Ltd (NASDAQ:GMDA), a stem cell company.

Menashe holds a bachelor degree in Pharmacy and a Ph.D. in Pharmaceutical Sciences from the Hebrew University of Jerusalem and completed his Post-doctoral fellowship in pharmaceutical chemistry at the University of California, San Francisco.